Logo image of TBI

TRUEBLUE INC (TBI) Stock Fundamental Analysis

NYSE:TBI - US89785X1019 - Common Stock

6.17 USD
+0.36 (+6.2%)
Last: 8/22/2025, 8:04:00 PM
6.17 USD
0 (0%)
After Hours: 8/22/2025, 8:04:00 PM
Fundamental Rating

3

TBI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 81 industry peers in the Professional Services industry. TBI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TBI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TBI has reported negative net income.
TBI had a negative operating cash flow in the past year.
In multiple years TBI reported negative net income over the last 5 years.
Of the past 5 years TBI 4 years had a positive operating cash flow.
TBI Yearly Net Income VS EBIT VS OCF VS FCFTBI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of TBI (-5.03%) is worse than 74.07% of its industry peers.
With a Return On Equity value of -11.09%, TBI is not doing good in the industry: 72.84% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -5.03%
ROE -11.09%
ROIC N/A
ROA(3y)-4.7%
ROA(5y)-4.52%
ROE(3y)-10.14%
ROE(5y)-10.07%
ROIC(3y)N/A
ROIC(5y)N/A
TBI Yearly ROA, ROE, ROICTBI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

TBI's Gross Margin of 24.92% is on the low side compared to the rest of the industry. TBI is outperformed by 66.67% of its industry peers.
TBI's Gross Margin has been stable in the last couple of years.
TBI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y-0.39%
TBI Yearly Profit, Operating, Gross MarginsTBI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20

More info and screens

5

2. Health

2.1 Basic Checks

TBI does not have a ROIC to compare to the WACC, probably because it is not profitable.
TBI has less shares outstanding than it did 1 year ago.
TBI has less shares outstanding than it did 5 years ago.
The debt/assets ratio for TBI is higher compared to a year ago.
TBI Yearly Shares OutstandingTBI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
TBI Yearly Total Debt VS Total AssetsTBI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

TBI has an Altman-Z score of 3.33. This indicates that TBI is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.33, TBI is doing good in the industry, outperforming 60.49% of the companies in the same industry.
TBI has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.18, TBI is doing good in the industry, outperforming 64.20% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z 3.33
ROIC/WACCN/A
WACC9.16%
TBI Yearly LT Debt VS Equity VS FCFTBI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

TBI has a Current Ratio of 1.94. This is a normal value and indicates that TBI is financially healthy and should not expect problems in meeting its short term obligations.
TBI has a Current ratio of 1.94. This is in the better half of the industry: TBI outperforms 71.60% of its industry peers.
TBI has a Quick Ratio of 1.94. This is a normal value and indicates that TBI is financially healthy and should not expect problems in meeting its short term obligations.
TBI has a better Quick ratio (1.94) than 71.60% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.94
TBI Yearly Current Assets VS Current LiabilitesTBI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

TBI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -650.00%.
Looking at the last year, TBI shows a very negative growth in Revenue. The Revenue has decreased by -13.01% in the last year.
Measured over the past years, TBI shows a decrease in Revenue. The Revenue has been decreasing by -7.93% on average per year.
EPS 1Y (TTM)-650%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)-13.01%
Revenue growth 3Y-10.33%
Revenue growth 5Y-7.93%
Sales Q2Q%0.02%

3.2 Future

The Earnings Per Share is expected to grow by 67.57% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 3.69% on average over the next years.
EPS Next Y-2.68%
EPS Next 2Y67.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1.26%
Revenue Next 2Y3.69%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TBI Yearly Revenue VS EstimatesTBI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B 2.5B
TBI Yearly EPS VS EstimatesTBI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 1 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TBI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 16.97 indicates a correct valuation of TBI.
Based on the Price/Forward Earnings ratio, TBI is valued a bit cheaper than the industry average as 60.49% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 35.82. TBI is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 16.97
TBI Price Earnings VS Forward Price EarningsTBI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBI Per share dataTBI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

A more expensive valuation may be justified as TBI's earnings are expected to grow with 67.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.57%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TBI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRUEBLUE INC

NYSE:TBI (8/22/2025, 8:04:00 PM)

After market: 6.17 0 (0%)

6.17

+0.36 (+6.2%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners97.73%
Inst Owner Change-3.26%
Ins Owners5.18%
Ins Owner Change0.46%
Market Cap184.48M
Analysts80
Price Target8.84 (43.27%)
Short Float %2.76%
Short Ratio3.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.09%
Min EPS beat(2)-24.74%
Max EPS beat(2)28.92%
EPS beat(4)3
Avg EPS beat(4)30.43%
Min EPS beat(4)-24.74%
Max EPS beat(4)87.81%
EPS beat(8)5
Avg EPS beat(8)32.46%
EPS beat(12)7
Avg EPS beat(12)24.26%
EPS beat(16)10
Avg EPS beat(16)26.45%
Revenue beat(2)1
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-2.04%
Max Revenue beat(2)1.19%
Revenue beat(4)1
Avg Revenue beat(4)-0.88%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)1.19%
Revenue beat(8)2
Avg Revenue beat(8)-1.29%
Revenue beat(12)2
Avg Revenue beat(12)-1.77%
Revenue beat(16)5
Avg Revenue beat(16)-0.89%
PT rev (1m)4%
PT rev (3m)8.33%
EPS NQ rev (1m)-342.86%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-15.82%
EPS NY rev (3m)-32.61%
Revenue NQ rev (1m)4.02%
Revenue NQ rev (3m)4.35%
Revenue NY rev (1m)1.39%
Revenue NY rev (3m)1.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 16.97
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)0.36
Fwd EY5.89%
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS51.33
BVpS10.21
TBVpS8.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.03%
ROE -11.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.92%
FCFM N/A
ROA(3y)-4.7%
ROA(5y)-4.52%
ROE(3y)-10.14%
ROE(5y)-10.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y-0.39%
F-Score3
Asset Turnover2.28
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.18%
Cap/Sales 1.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.94
Altman-Z 3.33
F-Score3
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)102.48%
Cap/Depr(5y)103.83%
Cap/Sales(3y)1.51%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-650%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y-2.68%
EPS Next 2Y67.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.01%
Revenue growth 3Y-10.33%
Revenue growth 5Y-7.93%
Sales Q2Q%0.02%
Revenue Next Year1.26%
Revenue Next 2Y3.69%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year114.44%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-197.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.55%
OCF growth 3YN/A
OCF growth 5YN/A